Literature DB >> 16514612

Response to paclitaxel, gemcitabine, and cisplatin in renal medullary carcinoma.

Moshe D Bell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16514612     DOI： 10.1002/pbc.20780

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  4 in total

Review 1.  The changing face of renal cell carcinoma pathology.

Authors:  Hakan Aydin; Ming Zhou
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

2.  Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats.

Authors:  Hazem E Hassan; Alan L Myers; Insong J Lee; Andrew Coop; Natalie D Eddington
Journal:  J Pharm Sci       Date:  2007-09       Impact factor: 3.534

3.  Response to radiation in renal medullary carcinoma.

Authors:  Alexandra M Walsh; John B Fiveash; Alyssa T Reddy; Gregory K Friedman
Journal:  Rare Tumors       Date:  2011-07-21

4.  Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression.

Authors:  Jacob S Lipkin; Syed M Rizvi; Zoran Gatalica; Nabeel E Sarwani; Sheldon L Holder; Mathew Kaag; Joseph J Drabick; Monika Joshi
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.